#meded | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Posts Tagged ‘#meded’

1:45PM 11/12/2014 – Panel Discussion – Oncology @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

Posted in Academic Publishing, Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage, tagged #endcancer, #meded, anti-cancer therapy, Big data, biochemotherapy, Bioinformatics, Chemogenomics, genomic drug development, genomics, health outcomes research, Huntsman Intermountain, MD Anderson Cancer center, medical education, Medical Ethics, oncology, Personalized medicine, Targeted therapy on November 12, 2014| Leave a Comment »

1:45PM 11/12/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

Reporter: Aviva Lev-Ari, PhD, RN

REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com

1:45 p.m. Panel Discussion – Oncology

Oncology

There has been a remarkable transformation in our understanding of the molecular genetic basis of cancer and its treatment during the past decade or so. In depth genetic and genomic analysis of cancers has revealed that each cancer type can be sub-classified into many groups based on the genetic profiles and this information can be used to develop new targeted therapies and treatment options for cancer patients. This panel will explore the technologies that are facilitating our understanding of cancer, and how this information is being used in novel approaches for clinical development and treatment.

Oncology

Opening Speaker & Moderator:

Lynda Chin, M.D.
Department Chair, Department of Genomic Medicine
MD Anderson Cancer Center @MDAnderson #endcancer

Who pays for personalized medicine?
potential of Big data, analytics, Expert systems, so not each MD needs to see all cases, Profile disease to get same treatment
business model: IP, Discovery, sharing, ownership — yet accelerate therapy
security of healthcare data
segmentation of patient population
management of data and tracking innovations
platforms to be shared for innovations
study to be longitudinal,
How do we reconcile course of disease with personalized therapy
phenotyping the disease vs a Patient in wait for cure/treatment

Panelists:

Roy Herbst, M.D., Ph.D. @DrRoyHerbstYale

Ensign Professor of Medicine and Professor of Pharmacology;
Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital @YaleCancer

Development new drugs to match patient, disease and drug – finding the right patient for the right Clinical Trial

match patient to drugs
partnerships: out of 100 screened patients, 10 had the gene, 5 were able to attend the trial — without the biomarker — all 100 patients would participate for the WRONG drug for them (except the 5)
patients wants to participate in trials next to home NOT to have to travel — now it is in the protocol
Annotated Databases – clinical Trial informed consent – adaptive design of Clinical Trial vs protocol
even Academic MD can’t read the reports on Genomics
patients are treated in the community — more training to MDs
Five companies collaborating – comparison of 6 drugs in the same class
if drug exist and you have the patient — you must apply personalized therapy

Lincoln Nadauld, M.D., Ph.D.
Director, Cancer Genomics, Huntsman Intermountain Cancer Clinic @lnadauld @intermountain

@Stanford, all patients get Tumor profiles Genomic results, interpretation – deliver personalized therapy
Outcomes from Genomics based therapies
Is survival superior
Targeted treatment – Health economic impact is cost lower or not for same outcome???
genomic profiling of tumors: Genomic information changes outcome – adverse events lower
Path ways and personalized medicine based on Genomics — integration not yet been worked out

Question by Moderator: Data Management

Platform development, clinical knowledge system,
build consortium of institutions to share big data – identify all patients with same profile

See more at http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf

8:50AM 11/12/2014 – Keynote Speaker – CEO, American Medical Association @10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

Posted in Academic Publishing, Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research, Scientific & Biotech Conferences: Press Coverage, tagged #meded, American Medical Association, FDA, FDA new policies, Health Outcomes Liaisons, health outcomes research, Health policy, healthcare costs, medical education, Personalized medicine, pharmacogenomics, physician education on November 12, 2014| Leave a Comment »

8:50AM 11/12/2014 – 10th Annual Personalized Medicine Conference at the Harvard Medical School, Boston

Reporter: Aviva Lev-Ari, PhD, RN

REAL TIME Coverage of this Conference by Dr. Aviva Lev-Ari, PhD, RN – Director and Founder of LEADERS in PHARMACEUTICAL BUSINESS INTELLIGENCE, Boston http://pharmaceuticalintelligence.com

8:50 a.m. – Keynote Speaker – CEO, American Medical Association

The American Medical Association (AMA) has the largest number of practicing physicians of all specialties as its members and the organization plays a very important role in health care policy and education of medical professionals. AMA has been quite active in assessing the role of personalized medicine in the future of healthcare in all of its facets. Dr. Madara will talk about the status of AMA’s thinking about personalized medicine and his vision of how it might be able to transform medical care.

Keynote Speaker

James Madara, M.D. @AmerMedicalAssn

Executive Vice President and CEO, American Medical Association

AMA Strategy the context for PM – Outside looking in View applied

Mission statement: Promote Medicine 167 years since it was established. Societies of MDs – all population of American MDs, are members.

AMA developed:

CPT Curation – Billing of Procedures
Standard Procedure for Katrina and Emergency Medicine
Strategic Plan 110 active Projects to be compressed into three big ideas

Connect clinics with community – OUTCOMES, cooperation with CDC i.e., Diabetes, HTN (KaiserPermanente)
Medical education bring t to 21th century: Competence vs Time-in-Chair, 141 Medical Schools, teaching methods: Gaming/mobile, the lecture Hall in Medicine is poor form for education, Simulation methods, Clinical Research and Basic Research – blend across disciplines, platforms in Silicon Valley to create new TEACHING of MDs, Genomics must be incorporated, shifting from Inpatient to Outpatient to HOME, all training is for Inpatient – Nothing for HOME delivery of Care. 85% of all Medical School responded they need change in Teaching — 11 Excellence Medical Schools selected: Vanderbilt, MI, UCSF, UC Davis…
Make practice of medicine joyous again – installation in MDs Offices, optimize the efficiency of MDs reporting now emphasis on USABILITY

Doing through Partnership: PM in Nutrition is everywhere — it is a HYPE, Gartner Group Hype Cycle was used by the Speaker for an analogy with Personalized Medicine (PM)

SHAKE out for a steady state in PM mitigation the hype

Mixed perceptions of Cost effectiveness of Healthcare delivery – Growth of Health Spending by Component:
Center on Outcomes and Values: PM redefined: away from behavioral toward procedural (actions): i.e, CV death risk predicted by waist size –

Cost/Behavior: sweet-spots are the following

Pharmaconeconomics: Is cost effective and it does not involve behavior
Cancer
Laboratory Developed Tests (LDTs)

– need be approved by FDA – New challenge in PM

– AMA View: Medical services not Medical Devices, CLIA ensure the quality and Standards, it requires more than guidance, currently FDA has ONLY guidance

– See more at: http://personalizedmedicine.partners.org/Education/Personalized-Medicine-Conference/Program.aspx#sthash.qGbGZXXf.dpuf

@HarvardPMConf

#PMConf

@SachsAssociates